SCHEMBL6132912

SCHEMBL6132912

Cc1ccc(C[C@@H]2CN(Cc3ccccc3)CCN2C(=O)OC(C)(C)C)cc1C

nearest known ligand 0.52

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
NR1H2 P55055 2/20 0.52
NR1H3 Q13133 2/20 0.52
PARP1 P09874 1/20 0.48
DPP4 P27487 2/20 0.47
CA1 P00915 2/20 0.46
CA2 P00918 2/20 0.46
CA4 P22748 2/20 0.46
CA9 Q16790 2/20 0.46
HDAC1 Q13547 1/20 0.43
FAAH O00519 1/20 0.43
TP53 P04637 2/20 0.43
DPP7 Q9UHL4 1/20 0.42
DRD4 P21917 2/20 0.41
SIGMAR1 Q99720 1/20 0.41
ROCK1 Q13464 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5367138 0.92 NR1H2 (0.50) NR1H2NR1H3PARP1DPP4CA1
SCHEMBL8448438 0.90 NR1H2 (0.58) NR1H2NR1H3PARP1DPP4CA1
SCHEMBL6099695 0.90 NR1H2 (0.58) NR1H2NR1H3PARP1DPP4CA1
SCHEMBL8229118 0.89 NR1H2 (0.54) NR1H2NR1H3PARP1DPP4CA1
SCHEMBL6100941 0.88 NR1H2 (0.52) NR1H2NR1H3PARP1DPP4CA1
SCHEMBL6098997 0.88 NR1H2 (0.52) NR1H2NR1H3PARP1DPP4CA1
SCHEMBL3506136 0.87 NR1H2 (0.54) NR1H2NR1H3PARP1DPP4CA1
SCHEMBL3495123 0.87 NR1H2 (0.54) NR1H2NR1H3PARP1DPP4CA1
SCHEMBL6099031 0.87 NR1H2 (0.54) NR1H2NR1H3PARP1DPP4CA1
SCHEMBL5369120 0.87 NR1H2 (0.54) NR1H2NR1H3PARP1DPP4CA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6924278-B2 Heterocyclic carboxy amines such as (2R)-1-[3,5-Bis(trifluoromethyl)benzoyl]-4-[4-((3S)-3-ethylmorpholino)-2-butynyl]-2-[(1H-indol-3-yl)methyl]piperazine, used as substance P and neurokinin antagonist for prophylaxis of diseases FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-08-02 US disclosed
US-20050027121-A1 Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2005-02-03 US disclosed
US-20030114668-A1 AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-19 US disclosed
EP-0993457-A1 AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2000-04-19 EP disclosed
WO-1998057954-A1 AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1998-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050027121-A1 Aroyl-piperazine derivatives, their preparation and their use as tachykinin antagonists TAC3, TACR1, SSTR5 NR1H2 1872/4885NR1H3 2768/4885PARP1 3413/4885
US-20030114668-A1 AROYL-PIPERAZINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS TACHYKININ ANTAGONISTS TACR1, NPSR1, SSTR2 NR1H2 1018/4885NR1H3 1490/4885PARP1 2781/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.